Positive Interim Analysis

Good news and great hope for all patients suffering from chronic neuropathic pain comes from our portfolio company Algiax Pharmaceuticals.

The company announced a positive interim analysis of a Phase 2a study with its lead candidate AP-325 in chronic neuropathic pain. AP-325 is a small molecule aimed at reducing neuropathic pain by activating GABAA signaling.

We keep our fingers crossed for the further development of the study.

More information in the press release under the following Link

OCCIDENT Team explores Amsterdam Overview First Patient In
Want to learn more about OCCIDENT?



New OCCIDENT Website

Having sharpened our investor profile and revised our communi­cation, we get to the point: OCCIDENT – The Science Investor.